Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Research Outlines Key Factors Influencing the Adoption of New Evidence Into Medical Practice

National Pharmaceutical Council study published in Journal of Comparative Effectiveness Research

Washington, DC (July 10, 2013)—Research published today in the Journal of Comparative Effectiveness Research outlines influential factors that impact how quickly new medical evidence is adopted and put into practice by health care decision-makers.

“We’ve seen firsthand that when a celebrity like Angelina Jolie talks about breast cancer and genetics, people are listening and want to take action,” said National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD. “And while media attention is an important factor in the adoption of health care information, it isn’t the only one. Scientific issues, economic drivers, and the level of patient involvement in their therapy also play key roles.”

The research, “When Is Evidence Sufficient for Decision Making? A Framework for Understanding the Pace of Evidence Adoption and Application,” was written by Dr. Dubois, Michael Lauer, MD, Director, Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute, National Institutes of Health, and Eleanor Perfetto, PhD, MS, formerly of Pfizer Inc. and now at the University of Maryland School of Pharmacy.

According to the Institute of Medicine, it takes an average of 17 years for new data, or evidence, to become part of routine care. Using three well-documented cases in which new information was disseminated to the public—statins, drug-eluting stents and bone marrow transplantation for breast cancer—the authors developed a framework to determine which factors were most influential in changing clinical practice. Their framework includes the following considerations:

  • Validity, reliability, and maturity of the science: Is the current understanding of the particular condition and its treatment understood well enough so that new information can be taken into account?
  • Economic drivers that might influence adoption: Who is paying for the treatment? Is it being reimbursed? What marketing or detailing efforts were influential?
  • Rapid (or slow) incorporation into practice guidelines: How quickly—or slowly—were the results accepted by groups that develop guidelines?
  • Communication: Are the results being amplified by major media outlets, celebrities or social media?
  • Patients’ and providers’ ability to apply results to their needs: Can patients or providers apply published evidence to their decisions?

With billions of dollars being spent on comparative effectiveness research, the framework can be useful in helping organizations consider how to translate and disseminate research findings, noted Dr. Dubois. “It is important to consider the critical factors that affect adoption and help to optimize the pace with which new treatments and findings are brought into routine clinical practice,” he said.  

NPC will host a webinar to discuss the research and a related white paper developed by IMS Health on July 31, 2013, from 1 pm – 2 pm ET. Register for the webinar on NPC's website.

About the National Pharmaceutical Council:

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit and follow NPC on Twitter @npcnow.

Newsletter Volume

E.V.I.dently November 2015

MessageCan We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?Has biopharmaceutical innovation brought value and made a...
Newsletter Volume

E.V.I.dently October 2015

MessageWhat’s the Fuss About Evidence From Clinical Experience? Here’s Why It MattersAt a health care forum in Washington, DC, earlier this month,...
Newsletter Volume

E.V.I.dently September 2015

MessageValue Is in the Eye of the BeholderIn recent months, a number of health organizations have developed “value assessment frameworks,” which are...
Blog Post

#TBT: CER Collaborative & Environmental Trends

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
YouTube Videos

When Is Evidence Fit for Purpose? Closing Gaps Between Researchers, Payers

Despite multi-million dollar public and private investments to tap into big data and improve the evidence available for health care decision-making,...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
Blog Post

#TBT: CER Collaborative & Environmental Trends

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

Researchers Consider When Evidence Is Fit for Purpose at Concordium Meeting

Coming up at AcademyHealth’s inaugural Concordium 2015 meeting, look for Jennifer Graff, PharmD, NPC’s vice president for comparative effectiveness...
Blog Post

CER Tweets of the Week: Study on Six Potential EBM “Biases”; VBID "Gets Its Medicare Close-up" (August 31-September 4)

This week on Twitter, comparative effectiveness research (CER) stakeholders shared a study examining six potential biases against patients and carers...
Blog Post

CER Tweets of the Week: Agenda and Crowd-Sourced Topic for PCORI Annual Meeting, PPRN for Alzheimer’s Disease (August 24-28)

This week, comparative effectiveness research (CER) stakeholders tweeted details of the Patient-Centered Outcomes Research Institute’s (@PCORI)...

Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue

A study published in the September 2015 issue of The American Journal of Managed Care introduces a...

2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's fifth annual survey, "Comparative Effectiveness Research (CER) and the Environment for Health...
  • 1 of 12
  • >